10x Genomics heads into its third-quarter report with an unusual mismatch between its stock and its numbers. Shares have climbed nearly 84% since the last earnings release, while the S&P 500 has barely moved. Yet Wall Street expects revenue to slip slightly from a year ago and the quarterly loss to widen. When a stock nearly doubles on a forecast of shrinking sales, the report has to explain the gap, either by showing the rally reflects real business improvement or by revealing it ran ahead of the fundamentals.

The consensus calls for a loss of $0.29 per share on revenue of about $147.2 million, due after the close on November 5. That revenue figure would be down about 1.2% from the $149.0 million posted a year earlier and below the $151.0 million reported last quarter. On earnings, the expected loss is roughly 32% wider than the $0.22 loss a year ago and about twice the $0.14 loss from the second quarter. The Earnings Whisper of a $0.20 loss is notably better than consensus. That gap is too large to dismiss and suggests the more engaged part of the market doubts the loss will deteriorate as much as published estimates imply. Matching consensus may not be enough. The real test is landing near or better than the whisper.

Management's guidance is the strongest support for the bullish case. The company raised its 2026 revenue forecast to $610 million to $630 million from $600 million to $625 million, lifting the midpoint from $612.5 million to $620 million. The full-year consensus of about $614.5 million, though, sits in the lower half of the new range. Analysts have accepted the raise but have not fully bought into it. A third quarter at or above $147 million would make the midpoint look reachable. A clear shortfall would raise doubts about how much fourth-quarter strength the guidance requires. Any further change to the range will likely matter more than the quarter's results themselves.

The sequential pattern is just as important. Consensus expects revenue to fall from the prior quarter while losses roughly double. A slight revenue dip can reflect normal timing in instrument sales. A much wider loss, however, implies that spending is rising faster than the top line. If 10x keeps the loss closer to second-quarter levels, it would suggest cost discipline is holding and that the raised guidance is not being bought with heavier spending. If the loss comes in at or beyond consensus, the market may start asking whether the recent improvement can last.

Sentiment has warmed but remains measured, with the bullish reading rising to 22.1% from 14.4% ahead of the previous report. The technical picture shows a much hotter mood. At $83.62, the stock trades more than double its 200-day moving average of $39.92. Its post-earnings range of $44.39 to $102.81 sits far above the prior quarter's $19.82 to $50.34 band. The shares have also pulled back about 19% from that peak, so some excess has already been worked off, but the stock is nowhere near a breakout.

The central question is whether 10x Genomics can show that its raised outlook rests on durable demand rather than an easy comparison. Revenue in line with consensus, a loss nearer the whisper, and a reaffirmed or raised 2026 range would support the rally. Flat sales paired with a widening loss and a hesitant outlook would leave a stock that has nearly doubled with little fresh evidence to justify the move.